智通财经网·2025-11-12 11:53Group 1: Company Performance - BeiGene reported a revenue of 10.077 billion yuan for Q3 2025, representing a year-on-year increase of 41.1%, with a net profit of 689 million yuan [1] - For the first three quarters of 2025, BeiGene's revenue reached 27.595 billion yuan, up 44.2% year-on-year, with a net profit of 1.139 billion yuan [1] Group 2: Share Buyback and Capital Reduction - Century Huatong announced a plan to repurchase shares worth 500 million to 1 billion yuan, which will be fully canceled to reduce the registered capital, with a maximum price of 28.77 yuan per share [2] Group 3: Shareholding Changes - Shannon Chip announced that the Wuxi High-tech Zone New Energy Industry Development Fund reduced its holdings by 549,200 shares, decreasing its stake from 5.12% to 4.999985% [3] - Founder Electric reported that shareholder Zhang Min reduced his holdings by a total of 1.6324 million shares on November 10 and 12, 2025, representing 0.33% of the total share capital, leaving him with 24.7936 million shares, or 5% of the total [4] Group 4: Legal Issues - North Medical's chairman Xu Xiren was arrested for suspected criminal activity, with the board's operations remaining normal and no change in control [5] Group 5: Corporate Governance Changes - Jiuzhou Pharmaceutical elected Hua Lirong as the executive director and legal representative, following the transfer of significant equity stakes from her father [6] Group 6: Strategic Partnerships - Haibo Sichuang signed a strategic cooperation agreement with CATL, committing to procure a total of no less than 200 GWh of electricity from 2026 to 2028 [7][8] Group 7: Regulatory Approvals - Yiling Pharmaceutical's wholly-owned subsidiary received approval for the listing application of the raw material drug Memantine Hydrochloride, aimed at treating moderate to severe Alzheimer's disease [9]